Core Insights - Eliem Therapeutics, Inc. has been included in the Russell 2000® Index and the broader Russell 3000® Index as part of the annual reconstitution, effective immediately [4] - The Russell indexes are widely utilized by investment managers and institutional investors, with approximately US$9.1 trillion in assets benchmarked against Russell's U.S. indexes as of May 2024 [5] - Inclusion in the Russell indexes is seen as a significant milestone for Eliem, enhancing its visibility and credibility in the market [10] Company Overview - Eliem Therapeutics focuses on developing therapeutics for autoimmune-driven inflammatory diseases, particularly advancing TNT119, an anti-CD19 antibody aimed at a range of autoimmune diseases including systemic lupus erythematosus and immune thrombocytopenia [11] - The company aims to harness the potential of TNT119, which is designed to have enhanced effector function [10] Industry Context - FTSE Russell, the provider of the Russell indexes, has over 30 years of experience and is a leading global index provider, offering benchmarks for investment performance and creating ETFs, structured products, and index-based derivatives [3][5] - FTSE Russell employs a transparent, rules-based methodology for index design and governance, adhering to high industry standards [7]
Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes